Sterile Inflammation after Intravitreal Injection of Aflibercept in a Korean Population.

Bilateral Severe Sterile Inflammation with Hypopyon after Simultaneous Intravitreal Triamcinolone Acetonide and Aflibercept Injection in a Patient with Bilateral Marked Rubeosis Associated with Ocular Ischemic Syndrome. Case Rep Ophthalmol Med (2017) 0.75

Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63

Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84

Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med (2011) 19.42

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology (2012) 8.29

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.60

Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology (2010) 4.09

Intravitreal aflibercept for diabetic macular edema. Ophthalmology (2014) 3.49

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology (2013) 2.99

Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol (2007) 2.51

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology (2013) 2.40

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology (2012) 2.36

Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology (2014) 2.04

Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol (2008) 1.94

Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology (2008) 1.51

Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology (2014) 1.49

Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol (2008) 1.38

Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol (2008) 1.31

Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology (2013) 1.29

Sterile endophthalmitis after intravitreal injections. Mediators Inflamm (2012) 0.96

Aflibercept-related sterile inflammation. Ophthalmology (2013) 0.93

Uveitis following intravitreal bevacizumab: a non-infectious cluster. Ophthalmic Surg Lasers Imaging (2011) 0.90

Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol (2014) 0.84

Intraocular inflammation after intravitreal ranibizumab injections. Acta Ophthalmol (2011) 0.84

Frequency and characteristics of intraocular inflammation after aflibercept injection. Retina (2015) 0.82